Log In Sign up
The largest database of trusted experimental protocols

Ipro2 system

Manufactured by Medtronic
Visit Supplier
Sourced in United States

The IPro2 system is a continuous glucose monitoring device designed to measure and record glucose levels in individuals with diabetes. The device consists of a sensor that is inserted under the skin to measure glucose levels, and a monitor that displays and records the data. The IPro2 system is intended to provide healthcare professionals with valuable data to assist in the management of diabetes.

Automatically generated - may contain errors

Lab products found in correlation

Enlite, by Medtronic (2 mentions) Surestep blood glucose meter, by LifeScan (1 mentions)

5 protocols using ipro2 system

1

Continuous Glucose Monitoring for Surgery

Check if the same lab product or an alternative is used in the 5 most similar protocols
In the evening (5–6 pm) of the day before surgery, team researchers approached patients for informing and attaching CGM sensor (Enlite, iPro2 system, Medtronic®). The sensor was placed by Enlite serter at the lower abdominal area or other recommended area.[17 (link)] The sensor was removed after the 3rd postoperative day. The data were retrieved by docking the sensor with iPro2 digital recorder and connecting to Care link iPro website.
Sindhvananda W., Poopuangpairoj W., Jaiprasat T, & Ongcharit P. (2023). Comparison of Glucose Control by Added Liraglutide to Only Insulin Infusion in Diabetic Patient Undergoing Cardiac Surgery: A Preliminary Randomized-Controlled Trial. Annals of Cardiac Anaesthesia, 26(1), 63-71.
+ Open protocol
+ Expand
2

Acceptability of CGM in Pregnancy

Check if the same lab product or an alternative is used in the 5 most similar protocols
CGM was performed with the Medtronic iPro2 system (Medtronic, Northbridge, CA) [19 ]. Following iPro2 insertion on the abdomen, participants received instruction on performing device calibration, and SMBG with finger-prick glucose measurement at least twice daily. Participants were provided with daily logs for SMBG and instructed to record the timing of meals, exercise, and medication in a paper diary. The monitoring period consisted of 7 days, following which participants returned to the antenatal clinic to remove the monitor and complete a questionnaire regarding device acceptability (Supplementary material 1). The (nonvalidated) bespoke survey consisted of five questions regarding the overall acceptability as well as acceptability of insertion, wearing and removal and the likelihood of recommending CGM as a diagnostic test for other women in a Likert scale format of 0-5. A final free text box allowed participants to share any recommendation or comment.
Di Filippo D., Ahmadzai M., Chang M.H., Horgan K., Ong R.M., Darling J., Akhtar M., Henry A, & Welsh A. (2022). Continuous Glucose Monitoring for the Diagnosis of Gestational Diabetes Mellitus: A Pilot Study. Journal of Diabetes Research, 2022, 5142918.
+ Open protocol
+ Expand
3

Subcutaneous Glucose Monitoring Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
The iPro2 system (Medtronic Inc, Northridge, CA, USA) was used for subcutaneous interstitial glucose monitoring. The sensor (Enlite, Medtronic Inc) recorded glucose levels every 5 min for seven consecutive days, and was inserted on the first day and removed after 7 days, generating a daily record of 288 continuous sensor values. At least two capillary blood glucose readings per day were measured by using a Sure Step blood glucose meter (LifeScan, Milpitas, CA, USA) to calibrate the CGM system. TIR was defined as the percentage of time in the target glucose range of 3.9 to 10.0 mmol/L during the 7 days. Intraday glycemic variability (GV) parameters included the standard deviation (SD) of sensor glucose values, glucose coefficient of variation (CV), and mean amplitude of glycemic excursions (MAGE). CV was determined as SD divided by the mean glucose level. In addition, the arithmetic mean of the differences between consecutive nadirs and peaks was computed to determine the MAGE value. During the 7-day CGM period, all subjects adhered to the original therapy regimen and standard diet.
Zhao W., Lu J., Zhang L., Lu W., Zhu W., Bao Y, & Zhou J. (2022). Relationship between time in range and corneal nerve fiber loss in asymptomatic patients with type 2 diabetes. Chinese Medical Journal, 135(16), 1978-1985.
+ Open protocol
+ Expand
4

Continuous Glucose Monitoring in Type 1 DM

Check if the same lab product or an alternative is used in the 5 most similar protocols
After an overnight fast, the Type 1 DM group underwent 72-h CGM with the Ipro2 System (Medtronic, Northridge, CA), and a subcutaneous sensor (Enlite; Medtronic, Northridge, CA) for CGM was applied on the same day of SD-OCT analysis. From CGM data, the following indexes of GV were calculated [18 (link)]: standard deviation (SD); mean amplitude of glucose excursion (MAGE); J-index; mean absolute glucose (MAG); continuous overall net glycemic action (CONGA-1, -2 and -4); low blood glucose (LBGI) and high blood glucose index (HBGI); M value.
Picconi F., Parravano M., Ylli D., Pasqualetti P., Coluzzi S., Giordani I., Malandrucco I., Lauro D., Scarinci F., Giorno P., Varano M, & Frontoni S. (2017). Retinal neurodegeneration in patients with type 1 diabetes mellitus: the role of glycemic variability. Acta Diabetologica, 54(5), 489-497.
+ Open protocol
+ Expand
5

CGM Glycemic Control Assessment

Check if the same lab product or an alternative is used in the 5 most similar protocols
Data on daily glycemic control during a four-day window was obtained from a CGM, which was inserted at the first home visit by a study nurse. While HbA1c provides a retrospective measure of overall glycemic control over the past 2–3 months, it does not capture day-to-day blood glucose levels. The CGM used in the current study was the Medtronic iPro2 system, which is a blinded system developed for use by physicians to assess glycemic control rather than for home diabetes management. Therefore, participants did not have real-time access to blood glucose values, ensuring that they were not able to use information obtained from the CGM to make changes in diabetes management during the study period. From the CGM, we obtained a mean daily blood glucose level during the four-day cortisol collection period. Linear regression was used to replace six missing values for CGM mean blood glucose (M = 208.85 mg/dL, SD = 55.13).
Zilioli S., Ellis D.A., Carré J, & Slatcher R.B. (2017). Biopsychosocial Pathways Linking Subjective Socioeconomic Disadvantage to Glycemic Control in Youths with Type I Diabetes. Psychoneuroendocrinology, 78, 222-228.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!